$0.52
1.10% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US00444T1007
Symbol
TLPH
Sector
Industry

AcelRx Pharmaceuticals, Inc. Stock price

$0.52
+0.03 5.22% 1M
-0.19 27.01% 6M
-0.01 1.62% YTD
-0.56 52.26% 1Y
-4.58 89.89% 3Y
-28.28 98.21% 5Y
-67.68 99.24% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.01 1.12%
ISIN
US00444T1007
Symbol
TLPH
Sector
Industry

Key metrics

Market capitalization $10.57m
Enterprise Value $11.71m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 390.33
P/S ratio (TTM) P/S ratio 352.33
P/B ratio (TTM) P/B ratio 1.57
Revenue growth (TTM) Revenue growth -95.85%
Revenue (TTM) Revenue $30.00k
EBIT (operating result TTM) EBIT $-13.93m
Free Cash Flow (TTM) Free Cash Flow $-13.27m
Cash position $5.39m
EPS (TTM) EPS $-0.44
P/E forward negative
P/S forward 391.48
EV/Sales forward 433.70
Short interest 0.88%
Show more

Is AcelRx Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

AcelRx Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a AcelRx Pharmaceuticals, Inc. forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a AcelRx Pharmaceuticals, Inc. forecast:

Buy
100%

Financial data from AcelRx Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
0.03 0.03
95% 95%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 7.50 7.50
26% 26%
25,000%
- Research and Development Expense 6.45 6.45
16% 16%
21,500%
-14 -14
10% 10%
-46,433%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -14 -14
12% 12%
-46,437%
Net Profit -12 -12
18% 18%
-38,800%

In millions USD.

Don't miss a Thing! We will send you all news about AcelRx Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AcelRx Pharmaceuticals, Inc. Stock News

Neutral
Seeking Alpha
6 days ago
Talphera, Inc. (NASDAQ:TLPH ) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants Raffi Asadorian - Chief Financial Officer Vincent Angotti - Chief Executive Officer Shakil Aslam - Chief Medical Officer Conference Call Participants Operator Welcome to the Talphera First Quarter 2025 Financial Results Conference Call. This call is being webcast live via the Events page ...
Neutral
PRNewsWire
6 days ago
Cash and investments at March 31, 2025, as adjusted to include the proceeds from the first tranche of the private placement financing which closed on April 2, 2025, were $9.8 million Three new clinical study sites activated and screening patients thus far in 2025, with five additional sites expected by mid-year, for a total of 13 Conference call and webcast to be held Wednesday, May 14, 2025 at...
Neutral
PRNewsWire
13 days ago
SAN MATEO, Calif. , May 7, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release first quarter 2025 financial results after market close on Wednesday, May 14, 2025, then host a live webcast and conf...
More AcelRx Pharmaceuticals, Inc. News

Company Profile

AcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies use in medically supervised settings. Its products include sufentanil, DZUVEO, DSUVIA ZALVISO US and ZALVISO EU. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in Redwood City, CA.

Head office United States
CEO Vincent Angotti
Employees 13
Founded 2005
Website talphera.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today